Drug Database
Back to search

Netherlands· NL-1814bb8a51a9

Ilaris 150 mg/ml, oplossing voor injectie

A canakinumab product containing canakinumab, registered in Netherlands by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.

ATC L04AC08

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedIlaris 150 mg/ml, oplossing voor inje…ATCL04AC08REGISTER NO.NL-1814bb8a51a9PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about canakinumabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Canakinumab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AC08 (canakinumab), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search canakinumab products by name

Canakinumab · ATC L04AC08

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CANAKINUMAB
Manufacturer
Novartis Europharm Limited
Country
Netherlands (NL)
ATC code
L04AC08
ATC class
Canakinumab
Defined daily dose
2.7 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/09/564

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

374 interactions on record for canakinumab.

Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check canakinumab against other medicinesHow interaction checks work

Canakinumab · interactions on record

374 records

  • 30 severe
  • 337 moderate
  • 7 minor

Most severe, free to view

  • CladribineL01BB04severe
  • PrednisoloneA07EA01moderate
  • HydrocortisoneA07EA02moderate
  • PrednisoneA07EA03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Canakinumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All canakinumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ilaris
  • Liechtenstein · Ilaris
  • Norway · Ilaris

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a8140697-62cc-4d8e-9281-331a0d85268c
GET /v1/drugs/a8140697-62cc-4d8e-9281-331a0d85268c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Oplossing voor injectie",
  "route": "Subcutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Canakimumab",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119255",
  "excipients": [
    "HISTIDINE, (L-)",
    "HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
    "MANNITOL (D-) (E 421)",
    "POLYSORBAAT 80 (E 433)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "CANAKINUMAB"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/02/23",
  "procedure_number": "EMEA/H/C/001109",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/09/564",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about canakinumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console